Neurosearch
Executive Summary
Cell and gene therapy program will be spun off as NsGene, CEO Jorgen Buus Lassen announced Sept. 30 at the Warburg Dillon Read Global Life Sciences Conference. Researchers, partners and collaborative agreements will all be shifted to NsGene. The group is considering therapies for Parkinson's disease, including a neublastin secreting cell line for protective therapy, and restorative therapy with dopaminergic neuronal precursor cell lines. "We expect that within three years, we can be in clinical studies within those new cell lines," Lassen said. Neurosearch aims to have financing for the spin off complete by the end of the year